Feng Mao, Ph.d.
Vice President, Synermore Beijing
Synermore Biologics
Synermore Biologics
China
Biography
Feng Mao joined Synermore in 2013 and served as Vice President, Process Development in Synermore Beijing, bringing more than twenty years of biotechnology industry experience. Dr. Mao has worked on the development of approximately 25 different biologic drug candidates, including monoclonal antibodies, recombinant proteins， PEG-proteins and antibody drug conjugates. Prior to joining the company, Dr. Mao was the Vice President of process development in Cotimes Biotech, where he provided leadership to direct others in solving complex R&D problems and oversaw of analytical methods development, validation and transfer of analytical methods to QC in GMP site. Prior to Cotimes, Dr. Mao was the Vice President of process development in Shanghai Celgen Bio-Pharmaceutical, where he involved in regulatory filings to SFDA by writing and reviewing of the associated sections of BLA, and responding to the questions. Prior to Celgen, Dr. Mao held biologic drugs development positions at CMCICOS
Research Interest
Molecular Biology and Molecular Genetics
